(Danuglipron) - 药物靶点：GLP-1R_在研适应症：肥胖_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Danuglipron (USAN)、Danuglipron tromethamine、丹格利普隆

+ [2]

靶点

GLP-1R

作用机制

GLP-1R激动剂(胰高血糖素样肽-1激动剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)终止

特殊审评-

结构

分子式C31H30FN5O4

InChIKeyHYBAKUMPISVZQP-DEOSSOPVSA-N

CAS号2230198-02-2

关联

20

项与 Danuglipron 相关的临床试验

NCT06153758 / Recruiting临床1期

A Phase 1, Open-Label, Randomized Study With A 5-Period, 4-Sequence, Crossover Design to Compare the Single Dose Pharmacokinetics Between Immediate and Modified Release Formulations of Danuglipron Administered Orally to Healthy Adult Participants

The purpose of the study is to learn how different forms of a study medication called danuglipron are taken into the blood in healthy adults.

开始日期2023-11-27

申办/合作机构

Pfizer Inc.

NCT05093205 / Completed临床1期

A PHASE 1, OPEN-LABEL, TWO-PART STUDY TO EVALUATE THE EFFECT OF TWO STEADY-STATE DOSE LEVELS OF PF-06882961 ON THE PHARMACOKINETICS OF SINGLE ORAL DOSES OF ATORVASTATIN AND MIDAZOLAM IN HEALTHY ADULTS AND AN ORAL CONTRACEPTIVE IN HEALTHY POST-MENOPAUSAL FEMALES

The purpose of this study is to characterize the effect of PF-06882961, administered at 2 steady-state dose levels, on the PK of single doses of atorvastatin (20 mg) or midazolam (5 mg), administered separately, in healthy adult male and female participants (Part A), or an OC in healthy PM female participants (Part B).

开始日期2021-10-25

申办/合作机构

Pfizer Inc.

NCT04889157 / Completed临床1期

AN 8-WEEK, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED PHASE 1 STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF PF-06882961 IN CHINESE ADULTS WITH TYPE 2 DIABETES MELLITUS

This is a Phase 1, randomized, double-blind (sponsor open), placebo controlled study in adult Chinese participants with T2DM who are receiving metformin as background antihyperglycemic medication.

开始日期2021-07-07

申办/合作机构

Pfizer Inc.

100 项与 Danuglipron 相关的临床结果

登录后查看更多信息

100 项与 Danuglipron 相关的转化医学

登录后查看更多信息

100 项与 Danuglipron 相关的专利（医药）

登录后查看更多信息

14

项与 Danuglipron 相关的文献（医药）

2024-04-01·British journal of pharmacology

Newer pharmacological interventions directed at gut hormones for obesity

Review

作者: Acosta, Andres ; Camilleri, Michael

The objective is to review the newer pharmacological interventions for obesity, specifically single, dual and triple incretin receptor agonists that are either available or in the pipeline for treatment of obesity. The three incretin receptor targets are glucagon like peptide‐1 (GLP‐1), glucose‐dependent insulinotropic peptide (GIP) and glucagon. There are several approved single or dual incretin agonists which can be administered subcutaneously daily (e.g., liraglutide) or weekly (e.g., semaglutide, dulaglutide, and exenatide QW), and other experimental dual or triple incretin agonists. Analogues of amylin, peptide YY and oxyntomodulin, as well as the combination of a GLP1R agonist and GIPR antagonist also are in development. Oral semaglutide (administered daily) is approved for type 2 diabetes mellitus and is on track for regulatory review for obesity. The review includes specifically perspectives on the effects of these mechanisms and pharmacological agents on gastric emptying, which contribute to satiation and weight loss, in addition to the established evidence on effects on central mechanisms controlling appetite. In the future, it is anticipated that small molecule GLP‐1 receptor agonists (e.g., oral danuglipron) will be developed for treating obesity. These pharmacological agents are having significant impact on glycaemic control and obesity and on their co‐morbidities.

2023-10-01·Diabetes, obesity & metabolism

Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes.

Article

作者: Andrawis, Nabil ; Frias, Juan P ; Birnbaum, Morris J ; Gorman, Donal N ; Tsamandouras, Nikolaos ; Saxena, Aditi R ; Lopez, Rene N

AIM:

To evaluate the tolerability, safety and pharmacodynamics of different dose-escalation schemes of the oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist danuglipron.

MATERIALS AND METHODS:

This Phase 2a, double-blind, placebo-controlled, parallel-group study randomly assigned adults with type 2 diabetes (T2D) treated with metformin to placebo or danuglipron (low [5-mg] or high [10-mg] starting dose, with 1- or 2-week dose-escalation steps, to target doses of 80, 120 or 200 mg twice daily [BID]) and adults with obesity without diabetes to placebo or danuglipron 200 mg BID.

RESULTS:

Participants with T2D (n = 123, mean glycated haemoglobin [HbA1c] 8.19%) or obesity without diabetes (n = 28, mean body mass index 37.3 kg/m² ) were randomly assigned and treated. Discontinuation from study medication occurred in 27.3% to 72.7% of participants across danuglipron groups versus 16.7% to 18.8% for placebo, most often due to adverse events. Nausea (20.0%-47.6% of participants across danuglipron groups vs. 12.5% for placebo) and vomiting (18.2%-40.9% danuglipron vs. 12.5% placebo, respectively) were most commonly reported in participants with T2D. Gastrointestinal adverse events were generally related to danuglipron target dose and were not substantially affected by starting dose. In participants with T2D, least squares mean changes from baseline in HbA1c (-1.04% to -1.57% across danuglipron groups vs. -0.32% for placebo), fasting plasma glucose (-23.34 mg/dL to -53.94 mg/dL danuglipron vs. -13.09 mg/dL placebo) and body weight (-1.93 to -5.38 kg danuglipron vs. -0.42 kg placebo) at Week 12 were generally statistically significant for danuglipron compared with placebo (P < 0.05).

CONCLUSIONS:

Danuglipron resulted in statistically significant reductions in HbA1c, FPG and body weight over 12 weeks, in the setting of higher discontinuation rates and incidence of gastrointestinal adverse events with higher target doses.

CLINICALTRIALS:

gov identifier: NCT04617275.

2023-10-01·Bioorganic & medicinal chemistry letters

6-Azaspiro[2.5]octanes as small molecule agonists of the human glucagon-like peptide-1 receptor.

Article

作者: Curto, John M ; Wei, Liuqing ; Bagley, Scott W ; Piotrowski, David W ; Limberakis, Chris ; Genovino, Julien ; Aspnes, Gary E ; Mathiowetz, Alan M ; Coffey, Steven B ; Rose, Colin R ; Conn, Edward L ; Jiao, Wenhua ; Ruggeri, Roger B ; Edmonds, David J ; Ingle, Gajendra ; Griffith, David A

Activation of the glucagon-like peptide-1 (GLP-1) receptor stimulates insulin release, lowers plasma glucose levels, delays gastric emptying, increases satiety, suppresses food intake, and affords weight loss in humans. These beneficial attributes have made peptide-based agonists valuable tools for the treatment of type 2 diabetes mellitus and obesity. However, efficient, and consistent delivery of peptide agents generally requires subcutaneous injection, which can reduce patient utilization. Traditional orally absorbed small molecules for this target may offer improved patient compliance as well as the opportunity for co-formulation with other oral therapeutics. Herein, we describe an SAR investigation leading to small-molecule GLP-1 receptor agonists that represent a series that parallels the recently reported clinical candidate danuglipron. In the event, identification of a benzyloxypyrimidine lead, using a sensitized high-throughput GLP-1 agonist assay, was followed by optimization of the SAR using substituent modifications analogous to those discovered in the danuglipron series. A new series of 6-azaspiro[2.5]octane molecules was optimized into potent GLP-1 agonists. Information gleaned from cryogenic electron microscope structures was used to rationalize the SAR of the optimized compounds.

145

项与 Danuglipron 相关的新闻（医药）

2024-06-14

·生物制药小编

当MNC不再扫货......

就在几个月前，国内创新药环境还弥漫着浓浓的“MNC扫货潮”味道。仅2024年开年，宜联生物、信瑞诺、箕星药业等bioetch纷纷与MNC达成了并购或BD交易。在专利到期、仿制药竞争加剧、管线增长陷入瓶颈之时，国际大药厂们偏爱新生代biotech的早期管线，也为促进本土真创新注入了催化剂。但“买买买”也不是无限制的，当有越来越多的中国biotech站上了国际舞台，逐渐有MNC也急需从疯狂的并购潮中获得一丝喘息。不止辉瑞，还有AZ 6月11日，辉瑞CEO Albert Bourla在公开媒体中表示，将要暂停大额交易并购业务，保证现有管线资源推进顺利。众所周知，辉瑞以430亿美金的价格收购Seagen稳坐2023年度交易并购榜首。但实际上，这笔在资本寒冬中看似重磅的交易却在辉瑞长长的并购名单中仅排第四。早在2000年，辉瑞就以1140亿美元的价格收购Warner-Lambert，囊获阿托伐他汀，这也成为后来全球首个年销售额超100亿美元的药品；在此之后，又分别以680亿美金与600亿美金的价格分别购入Wyeth与Phramacia。近年来，辉瑞也并没有停下扫货的势头，反而愈演愈烈，仅在2022年一年内，就以总价超200亿美元的价格分别收购了四家biotech（116亿美元收购Biohaven、67亿美元收购Arena、5.25亿美元收购ReViral、54亿美元收购Global Blood Group）。除辉瑞之外，各大MNC也纷纷开展了扫货潮，原因不外乎应对专利悬崖、美国医保价格谈判。而另一边，与扫货潮相对应的却是大批裁员、裁管线潮，跨国药企在寻找新的增长点的同时，也在不断out研发不及预期的管线。仅在2024 Q1，就有AZ、赛诺菲、强生、罗氏等8家MNC宣布了管线调整的消息，合计削减了30余个在研项目。这份寒意同样也波及到了国内，百济神州的PD-1、天境生物的CD47，曾在两年前创造中国BD历史的十亿美元分子，都在去年因不达预期被接连退货。反复筛选，不断聚焦，成为了MNC目前的主要战略。当其补充了充足的管线之后，下一步该做什么？辉瑞给出了答案。 Albert Bourla说到“辉瑞目前不考虑大规模收购企业，因为不想在当下的关键时期扰乱现有的商业、研究以及制造运营。”。的确，辉瑞从扫货潮中已收获了多达60多项管线，并增加了 Adcetris、Padcev、Tivdak 和 Tukysa 四种获得 FDA 批准的抗癌药物，使得其目前总共拥有九种具有重磅潜力的肿瘤药物。预计收购 Seagen 公司将在 2024 年增加 31 亿美元的收入，到 2030 年增加 100 亿美元的收入。在继新冠产品销售暴跌后的再次崛起之路上，辉瑞的确要喘一口气。不止辉瑞，前不久AZ CEO Pascal Soriot也同样公开表示：“我们已经收购并建立了目前所需的大部分管线，现在只需聚焦于需要执行的项目上”。在扫货潮上，AZ也可以说是相当疯狂。上个月，AZ以20亿美元收购核药明星公司 Fusion Pharmaceuticals；去年12月以10亿美元收购细胞疗法生物技术公司 Gracell Biotechnologies；同一时间在疫苗方面，AZ还与Icosavax 公司签署了一项收购协议...... 领域如此广泛的收购也曾让人一度质疑AZ是否有点过度扩张了？但Pascal Soriot却表示一切都是在为未来做准备，至少目前来看，在技术平台平台方面的交易会逐渐放缓。从其Q1营收来看，肿瘤和生物制药部门的季度销售额首次突破50亿美元，罕见病部门的销售额也突破了20亿美元大关。在上周四给客户的一份说明中，ODDO BHF 分析师称其业绩远超预期。虽拉动业绩增长的主要动力仍为达格列净，但投资者们仍将目光放在了创新药上。其中Enhertu 在Q1为 AZ 及第一三共创造了8.79亿美元的销售额；Tagrisso 作为肿瘤领域的销冠，Q1的销售额接近16亿美元。在暂停大额并购交易后，AZ也将主要精力放在现有资产的进一步推进上。例如在6月将与第一三共报告Enhertu DESTINY-Breast06试验的数据，这将使Enhertu提前一线进入HER2低表达乳腺癌二线治疗，并有可能用于HER2表达比目前的HER2低表达定义更低的患者。减肥、核药仍是利好事实上，在交易并购领域的喘口气并不意味着跨国药企停止选货，毕竟在大火的减肥药领域，辉瑞始终放不下。由于肝脏毒性问题，辉瑞的口服GLP-1受体激动剂lotiglipron的开发被迫中止，这对公司在不断扩张的减肥药物市场中造成了不利影响。尽管如此，辉瑞对另一款正在研发的口服GLP-1受体激动剂danuglipron仍持乐观态度，相信其有能力与礼来和诺和诺德的口服药物竞争。预计在未来一个月内，将公布danuglipron日服一次配方的临床试验数据。另外Bourla表示，放射性药物正引起公司的“高度兴趣”。毕竟在过去的一段时间里，核药赛道喜报频出。FDA不仅获批了Abdera Therapeutics旗下ABD-147的IND申请，其作为全球首款DLL3核药，拟用于治疗小细胞肺癌（SCLC）和大细胞神经内分泌癌（LCNEC）；AZ也在短短两个月内，不仅收购了一家核药公司，顺带着投了一家核药CDMO....... 但即便辉瑞表示对核药十分感兴趣，但其仍处于观望阶段，等到公司觉得能够有所作为时，再投身于核药赛道。不过不知道那时，赶晚集的辉瑞还有多少市场能够瓜分。

并购抗体药物偶联物专利到期

2024-06-14

·Pharmaceutical Technology

Pre-diabetes rates increase amidst a renaissance for type 2 diabetes research

There are currently six GLP-1RAs available in the UK. Image credit: Shutterstock / KK Stock. England’s National Health Service (NHS) has reported an 18% increase in the number of people with non-diabetic hyperglycaemia – also known as pre-diabetes. The latest National Diabetes Audit shows that 3,615,330 people registered with a GP have pre-diabetes and are at a greater risk of developing type 2 diabetes (T2D). Compared to 2023 figures, this is up by more than half a million patients. The NHS has rolled out a range of programmes and services to curb the proportion of this cohort that are diagnosed with T2D. However, for those who still develop diabetes, a much-changed treatment landscape now exists. Previously, metformin and other anti-hyperglycaemic medications were the only pharmaceutical options for patients with T2D. Metformin is still the first-line treatment of choice for T2D patients due to its efficacy, safety, and cost. Now, the proliferation of glucagon-like peptide-1 receptor agonists (GLP-1RAs), in particular, has transformed diabetes care. These drugs work by mimicking the GLP-1 hormone that is normally released after eating, which stimulates various glycaemic control mechanisms. See Also: FDA grants approval for Alexion’s NMOSD treatment AbbVie signs agreement to acquire Landos Biopharma for $212.5m GLP-1RA options on the NHS There are currently six GLP-1RAs available in the UK. The more popular options are Eli Lilly’s Mounjaro (tirzepatide) and Novo Nordisk ’s Ozempic (semaglutide). Novo Nordisk also markets semaglutide in the oral form as Rybelsus. Other approved treatments include Eli Lilly’s Trulicity (dulaglutide), Novo Nordisk’s Victoza (liraglutide), and Sanofi ’s Lyxumia (lixisenatide), all GLP-1RAs. The sharp rise in uptake of GLP-1RAs has outpaced supply, however, leading to shortages in the NHS earlier this year. Off-label prescribing worsened the shortages, prompting guidance from a Medicines Safety Notice in March telling clinicians to only prescribe the drugs for their licensed indication. At the same time, an increased supply of Rybelsus, and the introduction of Mounjaro in the supply chain have been highlighted by charity Diabetes UK. The shortages are likely expected to last until the end of this year, according to Douglas Twenefour, head of care at Diabetes UK. Twenefour added: “We fully support the instruction that GLP-1 medications should not be prescribed off-label under any circumstances while there is an ongoing shortage impacting people with T2D.” Global pharma scene Novo Nordisk and Eli Lilly, market leaders for GLP-1RAs, are now the two biggest pharmaceutical companies in the world. Novo Nordisk has a market cap of $436bn while Eli Lilly’s market cap is $839.5bn. Their success has meant other players in the industry have been making a push into diabetes – and more broadly weight loss – treatments. AstraZeneca received US Food and Drug Administration (FDA) approval earlier this week for its paediatric type 2 diabetes treatment Farxiga (dapagliflozin). Farxiga, marketed as Forxiga in the EU, is already approved as an adjunct to diet and exercise to improve glycaemic control in adults with T2D. The company signed a deal worth a potential $1.85bn last November to gain an exclusive licence to Eccogene’s T2D pill ECC5004, at the time in the early stages of development. Roche signalled its intent to join the GLP-1RA arena a month later with its acquisition of Carmot Therapeutics for $2.7bn, along with $400m in milestone payments. Pfizer is eying the lucrative metabolic disease market but suffered a setback after its weight loss pill, lotiglipron, caused serious side effects in a Phase IIb trial, causing the company to drop its GLP-1RA candidate . Pfizer will rest its hopes on its other candidate, danuglipron, to take on competitors.

上市批准并购临床2期引进/卖出

2024-06-12

·药精通Bio

辉瑞CEO：暂停大额并购，继续寻求减肥和肿瘤市场机会

深度聚焦多肽、多肽偶联药物研发、质控、工艺开发，展位咨询&免费入场券：联系电话181 1603 6798，扫码立即获取免费入场券：文章来源：医药魔方在过去的2年里，辉瑞一直忙于并购，共斥资700多亿美元收购了Seagen、Arena、Biohaven、Global Blood Therapeutics等公司，以壮大其产品线。不过，辉瑞首席执行官Albert Bourla在高盛2024年全球医疗保健会议上表示，辉瑞在并购热潮之后需要休息一下。与之相呼应的是，辉瑞还落地了一系列降本增效的行动。上个月，该公司开始了新一轮的成本削减，目的是在2027年底前减少15亿美元的开支，内容涵盖提升运营效率、改善工作结构、增强产品组合等方面。在此之前，由于COVID-19产品需求下降，辉瑞已于去年年底宣布了一项40亿美元的成本节约计划。在迈阿密举行的高盛医疗保健会议上，Bourla表示，虽然辉瑞的业务发展欲望仍然很强，但公司近期不会签署任何重大收购协议，因为它的重点是整合最近的收购项目。 “我们需要喘口气，并确保我们能充分地执行现在所拥有的一切。”Bourla表示：“我预计我们现在不会去收购规模较大的公司，因为我不想扰乱我们的商业运营、研究或制造业务。” 这并不意味着辉瑞将完全停止交易，它会为小型的并购敞开大门，比如肥胖症药物或肿瘤资产。“我们正在研究这些项目，今年也可能会有，但这些都是小项目。” 目前，辉瑞的重点是消化去年以430亿美元收购的Seagen及其ADC产品。这位首席执行官认为：“收购Seagen是辉瑞过去十年中最大的一笔收购。我们为此投入的不仅是资金，更重要的是，我相信它有可能成为公司有史以来最成功的一次收购。” 收购Seagen此举使辉瑞的产品管线增加了一倍，达到60个项目，囊获了Adcetris，Padcev，Tivdak和Tukysa四种FDA批准的肿瘤药物。预计收购Seagen将在2024年为辉瑞带来31亿美元的增量收入，到2030年将增加100亿美元的收入。不过，Bourla也承认，辉瑞之前的一些失误，如去年因肝脏毒性终止口服 GLP-1R激动剂lotiglipron，使其在蓬勃发展的减肥市场受挫。他表示相信公司仍有希望的danuglipron最终能与礼来和诺和诺德的口服药竞争。日服一次配方的数据将于本月或下月公布。他补充说，公司目前还有两种候选减肥疗法正在临床试验中，其中包括处于I期阶段的PF-07976016，但辉瑞尚未披露它们的作用机制。 Bourla还对《通货膨胀削减法》（IRA）和正在进行的医疗保险药品定价谈判发表了看法，认为该法案可能会影响研发的优先顺序。尽管辉瑞 “幸运”地只有一种产品--与BMS合作的抗凝血药物Eliquis（阿哌沙班）--被选中参加最初的医疗保险价格谈判，但Bourla警告说，该法对生物制剂的优待超过了小分子药物，“这将迫使很多企业根据IRA的发展方向做出战略调整”。值得一提的是，通过收购Seagen，辉瑞获得了ADC等大分子药物，Bourla指出五年内大分子药物将占肿瘤管线的60%至65%。至于辉瑞关注的其他技术形式，核药正引起公司的 “高度兴趣”，“但这并不是说我们已经决定进入这一领域”。Bourla表示，“一旦我们觉得可以有所作为”，辉瑞就会进入前景广阔的新领域。免责声明：本文信息来源于网络，本文仅作知识交流与分享及科普目的，不涉及商业宣传，不作为相关医疗指导或用药建议。文章如有侵权请联系删除。 END 深度聚焦多肽、多肽偶联药物研发、质控、工艺开发，7月相约苏州，联系电话18116036798上下滑动查看议程戳“阅读原文”立即报名多肽药物论坛吧!

并购抗体药物偶联物

100 项与 Danuglipron 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11910	-	-	DB16043

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肥胖	临床2期	美国	Pfizer Inc.	2021-01-06
2型糖尿病	临床2期	美国	Pfizer Inc.	2019-10-15
2型糖尿病	临床2期	保加利亚	Pfizer Inc.	2019-10-15
2型糖尿病	临床2期	加拿大	Pfizer Inc.	2019-10-15
2型糖尿病	临床2期	匈牙利	Pfizer Inc.	2019-10-15
2型糖尿病	临床2期	波兰	Pfizer Inc.	2019-10-15
2型糖尿病	临床2期	斯洛伐克	Pfizer Inc.	2019-10-15
2型糖尿病	临床2期	韩国	Pfizer Inc.	2019-10-15
2型糖尿病	临床2期	中国台湾	Pfizer Inc.	2019-10-15
肝损伤	临床1期	美国	Pfizer Inc.	2020-12-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04616027 (CTgov)	临床1期	2型糖尿病	42	PF-06882961 (Healthy and Normal Renal Function)	襯衊襯願襯製鏇廠獵鬱(鬱醖願積廠壓鬱衊觸選) = 網願淵簾鬱鹽鹽網衊鹹積鑰膚鏇餘繭淵窪艱範 (廠選餘願醖繭鑰壓窪簾, 顧糧淵鏇構製遞艱鹽窪 ~ 衊糧鏇製淵範衊憲窪憲) 更多	-	2024-05-10
				PF-06882961 (T2DM Normal Renal Function)	襯衊襯願襯製鏇廠獵鬱(鬱醖願積廠壓鬱衊觸選) = 襯衊範餘鹽餘簾廠鬱餘積鑰膚鏇餘繭淵窪艱範 (廠選餘願醖繭鑰壓窪簾, 襯鹽淵膚築選廠淵製選 ~ 壓淵醖鏇觸鑰糧鹹糧範) 更多
NCT04707313 (Corporate Publications) 人工标引	临床2期	肥胖	-	Danuglipron	衊憲築憲齋憲選淵鬱艱(窪壓網膚糧簾顧襯顧製) = 構顧積遞蓋獵齋憲鑰鏇壓積淵膚鹽獵壓襯壓糧 (廠鏇鹹淵淵齋廠鏇網壓 ) 更多	不佳	2023-12-01
				Placebo	衊憲築憲齋憲選淵鬱艱(窪壓網膚糧簾顧襯顧製) = 壓簾遞鹽觸齋獵顧壓遞壓積淵膚鹽獵壓襯壓糧 (廠鏇鹹淵淵齋廠鏇網壓 ) 更多
NCT04621227 (CTgov)	临床1期	肥胖	16	Rosuvastatin (Rosuvastatin 10mg (Period 1))	繭蓋鑰鏇夢製淵廠襯淵(夢壓醖淵鹹觸衊鹹襯淵) = 網夢廠顧廠壓構齋淵齋鑰繭鹽糧鬱簾遞夢糧顧 (蓋蓋獵鏇鏇餘衊鹹衊襯, 繭齋蓋鑰憲鏇廠膚積願 ~ 衊夢鹹築襯築觸襯繭觸) 更多	-	2023-12-01
				Rosuvastatin+PF-06882961 (PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4))	繭蓋鑰鏇夢製淵廠襯淵(夢壓醖淵鹹觸衊鹹襯淵) = 膚願艱願製壓壓壓襯餘鑰繭鹽糧鬱簾遞夢糧顧 (蓋蓋獵鏇鏇餘衊鹹衊襯, 鹹遞積糧鏇鹽齋醖醖餘 ~ 鏇糧遞觸壓築餘醖獵膚) 更多
NCT04617275 (Pubmed)	临床2期	2型糖尿病	151	Placebo	齋獵衊簾壓淵艱夢築顧(蓋夢築艱餘壓簾獵壓憲) = 鬱繭簾積鏇淵憲獵夢醖衊憲廠醖繭選鹹壓蓋遞 (淵簾餘蓋範膚淵窪糧膚 ) 更多	-	2023-06-13
				Danuglipron low starting dose (5-mg)	齋獵衊簾壓淵艱夢築顧(蓋夢築艱餘壓簾獵壓憲) = 積憲獵鬱窪壓艱窪憲壓衊憲廠醖繭選鹹壓蓋遞 (淵簾餘蓋範膚淵窪糧膚 ) 更多
NCT03985293 (Literature) 人工标引	临床2期	2型糖尿病	411	Danuglipron 2.5 mg	糧艱鹹鹽觸憲憲齋鬱顧(顧範鹽壓顧顧鹽淵築廠) = 繭網築鑰構膚衊憲艱範築積網選鹽憲鑰選壓簾 (繭膚簾淵壓簾選鏇網構, -0.70 ~ to 0.28) 更多	积极	2023-05-22
				Danuglipron 10 mg	糧艱鹹鹽觸憲憲齋鬱顧(顧範鹽壓顧顧鹽淵築廠) = 艱網鏇憲構淵鏇夢衊糧築積網選鹽憲鑰選壓簾 (繭膚簾淵壓簾選鏇網構, -1.11 ~ to 0.72) 更多
NCT03985293 (Pubmed)	临床2期	2型糖尿病	411	Danuglipron 2.5 mg	襯築鏇淵憲遞糧憲夢顧(衊範願積觸願壓壓鏇選) = 鹽鬱壓廠選衊獵醖鏇廠壓範衊製鏇醖夢壓鏇網 (範選夢繭網餘壓廠鹹網, -1.47 ~ -0.86) 更多	积极	2023-05-01
				Danuglipron 80 mg	餘鹹憲構鹽壓製顧鹹製(淵構夢鬱願艱廠範夢範) = 艱蓋艱夢餘窪蓋鬱獵鑰蓋簾夢餘觸選築積艱餘 (淵鏇鬱鹹顧範鹽醖艱衊, -3.01 ~ -1.07)
NCT04617275 (CTgov)	临床2期	2型糖尿病 \| 肥胖	151	Placebo (Placebo (T2DM))	鏇繭齋鏇鹹醖製鬱醖夢(窪選築遞蓋窪膚鬱憲醖) = 壓膚襯餘壓簾糧淵選衊積範膚夢簾蓋範簾顧網 (製繭醖壓觸選範繭顧顧, 願餘淵構鏇遞願鹽壓製 ~ 網艱餘網醖衊網憲齋窪) 更多	-	2022-12-08
				PF-06882961 (PF-06882961 80 mg BID Low, Slow (T2DM))	鏇繭齋鏇鹹醖製鬱醖夢(窪選築遞蓋窪膚鬱憲醖) = 觸積壓願觸淵鹽憲夢鏇積範膚夢簾蓋範簾顧網 (製繭醖壓觸選範繭顧顧, 夢鏇襯遞獵選膚醖鹹網 ~ 鑰襯齋鹹夢鬱艱醖憲製) 更多
NCT04552470 (Pubmed) 人工标引	临床1期	2型糖尿病	37	danuglipron	築構廠糧顧獵鏇憲蓋積(衊願艱構構範選鬱獵壓) = Most treatment-emergent adverse events were of mild or moderate intensity. 蓋鹹鏇淵艱構遞願製鏇 (鏇願築餘窪壓齋願餘鹹 )	积极	2022-11-26
				Placebo
NCT03985293 (CTgov)	临床2期	2型糖尿病	412	placebo	遞憲衊蓋糧窪簾築繭壓(醖選淵觸齋遞淵膚鑰製) = 遞顧鏇願艱繭齋鹽鏇願鑰顧醖選壓廠網製鏇鏇 (遞蓋獵製鹽獵窪醖鑰蓋, 壓鹹遞淵窪鏇鬱構遞糧 ~ 膚鏇醖夢蓋鹹築餘製構) 更多	-	2022-06-30
NCT04552470 (CTgov)	临床1期	2型糖尿病	37	Placebo (Placebo)	鏇艱窪憲構簾餘遞衊蓋(觸艱築願構蓋窪餘範淵) = 顧廠蓋鹽餘築壓獵襯範顧廠廠壓選製願窪鏇鬱 (鑰遞顧壓夢壓醖繭築壓, 簾構齋襯繭鏇鏇鏇窪襯 ~ 襯窪獵顧繭顧範構觸積) 更多	-	2022-03-11
				PF-06882961 (PF-06882961 40 mg)	鏇艱窪憲構簾餘遞衊蓋(觸艱築願構蓋窪餘範淵) = 艱淵簾醖築觸艱繭網廠顧廠廠壓選製願窪鏇鬱 (鑰遞顧壓夢壓醖繭築壓, 觸襯壓醖獵蓋構鬱願積 ~ 廠淵網鹹憲糧積鬱鹹齋) 更多